The sermorelin half-life is one of the most practically important numbers in the compound’s published pharmacology — and one of the shortest in the GH-secretagogue family. How long a peptide survives in circulation determines the shape of the signal it delivers, the design of studies that use it, and the entire engineering rationale behind its longer-acting successors. This article reviews the sermorelin half-life strictly as published pharmacokinetic data: the reported values, how they were measured, how the peptide is cleared, and how it compares to related compounds. Research framing throughout — no dosing guidance, no human-use advice, just the numbers and what the literature says about them.
Research-use-only disclaimer: Sermorelin is not currently an FDA-approved medicine. It is discussed here strictly as a research compound. This article reports published pharmacokinetic parameters; it contains no dosage information, no administration instructions, and no medical advice.
Sermorelin Half-Life: The Reported Numbers
Published sources report the sermorelin half-life within a consistent, narrow band — unusually good agreement for a peptide parameter. A published pharmacology review of growth hormone secretagogues records, for sermorelin administered intravenously and subcutaneously in humans: Tmax of 5–20 minutes and a terminal half-life (T1/2) of 11–12 minutes after subcutaneous administration. Other published summaries place the sermorelin half-life at roughly 10–20 minutes in humans, while some sources cite values under 10 minutes — “perhaps as low as 5 minutes” in one secondary summary. The honest reading: the sermorelin half-life is on the order of minutes, most carefully measured at 11–12 minutes, with the exact figure depending on route, assay, and study population.
T1/2 ≈ 11–12 minutes (subcutaneous, humans)
The most specific published figure for the sermorelin half-life comes from a pharmacology review tabulating human data: 11–12 minutes terminal half-life after subcutaneous administration. This is the number researchers cite when they need a single value — with the caveat that other studies report a 10–20 minute range.
Tmax ≈ 5–20 minutes
The same published review records time-to-peak plasma concentration of 5–20 minutes. Combined with the short sermorelin half-life, this describes a rapid-in, rapid-out profile: the peptide peaks quickly and is substantially cleared within about an hour — a brief, self-limited signal to the pituitary.
Range across sources: ~5 to ~20 minutes
Why the spread? Peptide half-life measurements depend on the assay’s sensitivity, the sampling schedule (sparse early sampling misses the true peak), the route of administration, and inter-individual differences in renal function and peptidase activity. For a peptide cleared this fast, small methodological differences move the number. The literature’s consensus is directional, not decimal: the sermorelin half-life is very short — minutes, not hours.
How Sermorelin Is Cleared: Renal Filtration and Enzymatic Clipping
The sermorelin half-life is short for two documented reasons, and published summaries name both. First, renal ultrafiltration: at ~3,358 Da, sermorelin is far below the kidney’s filtration cutoff, so circulating peptide is filtered out of plasma rapidly. Second, enzymatic degradation at the N-terminus: peptidases clip the peptide near its front end, and published descriptions identify this N-terminal cleavage as the primary enzymatic route destroying the molecule’s activity. Together — fast filtration plus fast clipping — they explain why the sermorelin half-life is measured in minutes.
This two-route clearance is also the reason the entire GHRH-analogue field looks the way it does. Every engineered successor to sermorelin is, at bottom, an attempt to slow one or both of these processes: the tetrasubstituted GRF(1-29) swaps four amino acids specifically to resist the N-terminal enzyme, while other designs add bulk or binding moieties to reduce renal filtration. Understanding the sermorelin half-life means understanding the problem statement the whole analogue family was built to solve. Researchers can follow the underlying pharmacology through studies indexed on PubMed.
Sermorelin Half-Life vs. Related Compounds
Numbers mean more in context. The table below places the sermorelin half-life alongside published half-life figures for related GH-axis compounds — the natural hormone it mimics, its engineered successors, and one compound from the other receptor pathway for scale.
| Compound | Class / relationship to sermorelin | Published half-life | What the number reflects |
|---|---|---|---|
| Endogenous GHRH (44 aa) | The natural hormone sermorelin fragments | Roughly 7 minutes (reported) | Full-length molecule with intact N-terminal cleavage site; cleared even faster than the fragment |
| Sermorelin | GRF(1-29); the reference compound | 11–12 min (10–20 min range in some sources) | Shorter than the successors below — the baseline of the family |
| Modified GRF(1-29) | Tetrasubstituted analogue (positions 2, 8, 15, 27) | At least 30 minutes | Four amino-acid swaps resist the N-terminal enzyme (Wikipedia) |
| Tesamorelin | Stabilized GHRH analogue (Egrifta) | 26–38 minutes | N-terminal modification increases stability (Wikipedia) |
| Ipamorelin | Ghrelin-receptor agonist (different pathway) | ~2 hours | Different receptor, different chemistry — shown for scale, not direct comparison |
The pattern is unmistakable: each generation of GHRH analogue buys more minutes, and each buys them by attacking the same two clearance routes behind the sermorelin half-life. The table also shows why half-life comparisons across receptor classes (the ipamorelin row) need care — different receptors, different signaling, different research questions. Within the GHRH family, though, the ranking is clean and the literature agrees on it.
Half-life is not effect duration
A common misreading: assuming the GH pulse lasts only as long as the sermorelin half-life. In published descriptions, the peptide is the trigger, not the effect — it initiates a pituitary signaling cascade (cAMP, calcium influx, vesicle release) and a downstream GH pulse that outlasts the peptide’s presence in plasma. The signal is brief; the gland’s response follows its own physiology, shaped by somatostatin and IGF-1 feedback. Researchers modeling sermorelin studies distinguish the pharmacokinetic half-life from the pharmacodynamic response.
Why Such a Short Half-Life Matters in Research
The sermorelin half-life is not just a number to memorize — it shapes what the compound is useful for in research settings. Three implications appear repeatedly in the published discussion.
First, pulsatility. Because the peptide clears within about an hour, each exposure is a discrete pulse rather than a sustained signal. Published summaries describe this as producing a short, self-limited stimulus to the pituitary, after which the gland returns to its own regulated rhythm. For researchers studying pulsatile GH physiology, that brevity is a feature: the compound probes the system without overriding it.
Second, the diagnostic rationale. Sermorelin’s former diagnostic role depended on this profile — a rapid, standardized stimulus followed by timed GH measurements. The short sermorelin half-life meant the test measured the pituitary’s response to a defined pulse, not its behavior under prolonged stimulation. (Historical context only; the diagnostic product was discontinued in 2008.)
Third, the analogue benchmark. In comparative pharmacology, the sermorelin half-life is the reference point: every longer-acting GHRH analogue is evaluated partly by how many minutes it adds and at what cost in complexity. Modified GRF(1-29) roughly triples it; tesamorelin extends it further with a different chemistry. Without the sermorelin baseline, those improvements have no scale.
The same research-use framing used here applies across this site’s literature reviews: our Selank vs Semax research comparison, our Semax nasal spray research overview, and our Selank nasal spray research overview all report published parameters without human-use guidance. And the FDA’s drug information pages remain the reference for what approval status means for any compound discussed here.
Key Takeaways: Sermorelin Half-Life
Research summary — not a usage recommendation
- The published sermorelin half-life is 11–12 minutes (terminal, subcutaneous, humans), with a 10–20 minute range across sources and some reports under 10 minutes.
- Tmax is 5–20 minutes; the peptide is substantially cleared within about an hour — a rapid-in, rapid-out profile.
- Clearance runs through two documented routes: renal ultrafiltration (small peptide, ~3,358 Da) and N-terminal enzymatic degradation.
- Every engineered successor (Modified GRF 1-29, tesamorelin) extends the sermorelin half-life by attacking those same two routes — sermorelin is the family’s baseline.
- Half-life is not effect duration: the GH pulse the peptide triggers outlasts the peptide itself, shaped by pituitary feedback physiology.
Sermorelin Half-Life: Frequently Asked Questions
Quick answers to the questions that come up most about the sermorelin half-life — all in research framing.
What is the half-life of sermorelin?
Published pharmacology data report a terminal half-life of 11–12 minutes after subcutaneous administration in humans, with other sources citing a 10–20 minute range and some reports under 10 minutes. The consensus across the literature is that the sermorelin half-life is measured in minutes — very short by peptide standards.
Why is sermorelin’s half-life so short?
Two documented clearance routes: renal ultrafiltration (the ~3,358 Da peptide is rapidly filtered from plasma) and enzymatic degradation at the N-terminus, where peptidases clip the molecule and destroy its activity. Both routes are described in published pharmacology summaries.
How does sermorelin’s half-life compare to Modified GRF(1-29)?
Modified GRF(1-29) — the tetrasubstituted analogue with amino-acid swaps at positions 2, 8, 15, and 27 — has a published half-life of at least 30 minutes, roughly triple the sermorelin half-life. The substitutions were designed specifically to resist the N-terminal enzymatic cleavage that limits sermorelin.
Does the short half-life mean sermorelin’s effects are equally short?
Not exactly. The peptide is the trigger, not the effect: it initiates pituitary GH release through a signaling cascade, and the resulting GH pulse outlasts the peptide’s plasma presence. Researchers distinguish the pharmacokinetic sermorelin half-life from the longer pharmacodynamic response shaped by somatostatin and IGF-1 feedback.
What is sermorelin’s Tmax?
Published human data report time-to-peak plasma concentration (Tmax) of 5–20 minutes. Combined with the short half-life, this describes a rapid-in, rapid-out exposure profile.
Where can researchers verify these pharmacokinetic figures?
The 11–12 minute figure comes from a published pharmacology review of growth hormone secretagogues tabulating human IV/SC data; related figures appear in secondary summaries and analogue-comparison literature. Studies are indexed on PubMed for direct verification.
Sermorelin Half-Life: Final Research Notes
The sermorelin half-life — about 11–12 minutes, minutes not hours — is the single number that explains the most about this compound’s place in research. It explains why the signal is pulsatile rather than sustained, why the diagnostic test worked the way it did, and why an entire family of engineered analogues exists to extend it. It is also a reminder of how precisely the literature has characterized this peptide: Tmax, clearance routes, comparative rankings, and the honest spread between sources are all on the record. For a research compound, that depth of pharmacokinetic documentation is the point — and the sermorelin half-life is where that documentation starts.
Laboratories working with research compounds under the standard applied throughout this review can see the same research-use-only framing on our Semax 10mg and Selank 10mg listings.
